Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) EBT Margin (2018 - 2025)

BioNexus Gene Lab's EBT Margin history spans 8 years, with the latest figure at 27.87% for Q3 2025.

  • For Q3 2025, EBT Margin rose 2322.0% year-over-year to 27.87%; the TTM value through Sep 2025 reached 25.05%, down 1512.0%, while the annual FY2024 figure was 16.77%, 992.0% up from the prior year.
  • EBT Margin for Q3 2025 was 27.87% at BioNexus Gene Lab, down from 27.26% in the prior quarter.
  • Across five years, EBT Margin topped out at 79.55% in Q1 2021 and bottomed at 99.18% in Q3 2023.
  • The 5-year median for EBT Margin is 3.51% (2024), against an average of 8.27%.
  • The largest annual shift saw EBT Margin plummeted -99066bps in 2021 before it skyrocketed 4809bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 6.07% in 2021, then crashed by -174bps to 4.49% in 2022, then soared by 349bps to 11.16% in 2023, then tumbled by -250bps to 16.72% in 2024, then plummeted by -67bps to 27.87% in 2025.
  • Per Business Quant, the three most recent readings for BGLC's EBT Margin are 27.87% (Q3 2025), 27.26% (Q2 2025), and 29.17% (Q1 2025).